Beijing Tiantan Biological Products Corporation (600161.SH): Termination of intravenous COVID-19 human immunoglobulin (pH4) clinical trial.

Beijing Tiantan Biological Products Corporation (600161.SH) announced that the "Intravenous COVID-19 Human Immunoglobulin (pH4)" developed by its subsidiary Wuhan Biopharmaceutical Co., Ltd. of China National Pharmaceutical Group is in Phase II clinical trial research stage. Recently, after comprehensive evaluation, the company has decided to terminate the Phase II clinical trial research and further development of this drug. It is reported that the total investment in the development of Intravenous COVID-19 Human Immunoglobulin (pH4) amounted to 120.607 million yuan, including research and development expenses and equipment purchase fees. The accumulated research and development expenses amount to 116.9095 million yuan, of which 116.9099 million yuan has been included in previous years' financial statements, and -0.04 million yuan will be included in the financial statements of 2024. The termination of the clinical trials and further development of Intravenous COVID-19 Human Immunoglobulin (pH4) will not have a significant impact on the company's future production, operation, and performance.